Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 40Carcinoma, Non-Small-Cell Lung 35Lung Neoplasms 13Neoplasms 12Adenocarcinoma 11Neoplasm Metastasis 10Colorectal Neoplasms 9Esophageal Neoplasms 7Carcinoma, Hepatocellular 7Colonic Neoplasms 5Carcinoma, Renal Cell 5Breast Neoplasms 5Adenocarcinoma Of Esophagus 5Urinary Bladder Neoplasms 3Urethral Neoplasms 3Rectal Neoplasms 3Melanoma 3Liver Neoplasms 3Carcinoma, Transitional Cell 3Biliary Tract Neoplasms 3Ureteral Neoplasms 2Thymoma 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Sarcoma 2Recurrence 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Non-small Cell Lung Cancer Metastatic 2Metastatic Gastric Adenocarcinoma 2

Interventions

trifluridine tipiracil drug combination 1berzosertib 1Trifluridine 1Taxes 1Ramucirumab 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Irinotecan 1Endoscopy 1Endoscopic Mucosal Resection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clinical Stage III Gastric Cancer AJCC v8 × Ramucirumab × Clear all
NCT04660760 2024-04-01

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

Academic and Community Cancer Research United

Phase 2 Unknown
116 enrolled
Gastrointestinal

Clinical Stage III Gastric Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡